The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Targeting HSP90 for cancer therapy
Open accessAbstract
Heat-shock proteins (HSPs) are molecular chaperones that regulate protein folding to ensure correct conformation and translocation and to avoid protein aggregation. Heat-shock proteins are increased in many solid tumours and haematological malignancies. Many oncogenic proteins responsible for the transformation of cells to cancerous forms are client proteins of HSP90. Targeting HSP90 with chemical inhibitors would degrade these oncogenic proteins, and thus serve as useful anticancer agents. This review provides an overview of the HSP chaperone machinery and the structure and function of HSP90. We also highlight the key oncogenic proteins that are regulated by HSP90 and describe how inhibition of HSP90 could alter the activity of multiple signalling proteins, receptors and transcriptional factors implicated in carcinogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“Over 50% of human cancers possess mutated p53 and in particular are associated with the more aggressive or chemotherapeutic resistant tumours (Vogelstein et al, 2000).”
BackgroundClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product
Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M.-L., Kmiecik, T. E., Vande Woude, G. F., & Aaronson, S. A. (1991) · Science · doi:10.1126/science.1846706 · Cited by 2,236
Pratt, W. B., & Toft, D. O. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800201 · Cited by 1,483
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Small heat shock proteins are molecular chaperones.
Jakob, U., Gaestel, M., Engel, K., & Buchner, J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53882-5 · Cited by 1,376
HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153 · cited 1×
“Hyperacetylation attenuates HSP90 chaperoning of client proteins BCR-ABL, AKT, RAF1 and hormone receptors, such as the glucocorticoid receptor results in cellular cytotoxicity (Kovacs et al, 2005; Fiskus et al, 2007; Wandinger et al, 2008).”
BackgroundPathways of chaperone-mediated protein folding in the cytosol
Young, J. C., Agashe, V. R., Siegers, K., & Hartl, F. U. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1492 · Cited by 1,105
Modulation of Akt kinase activity by binding to Hsp90
Sato, S., Fujita, N., & Tsuruo, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170276797 · Cited by 967
Weidemann, A., & Johnson, R. S. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.12 · Cited by 941
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of Carcinogenesis
Dai, C., Whitesell, L., Rogers, A. B., & Lindquist, S. (2007) · Cell · doi:10.1016/j.cell.2007.07.020 · Cited by 826
Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally
Zhang, Y., Kwon, S., Yamaguchi, T., Cubizolles, F., Rousseaux, S., Kneissel, M., Cao, C., Li, N., Cheng, H.-L., Chua, K., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01154-06 · Cited by 559 · cited 1×
“Hyperacetylation of HSP90 occurs following histone deacetylase 6 (HDAC6) inhibition and is observed in HDAC6-deficient mouse embryonic fibroblasts and correlates with impaired HSP90 function (Zhang et al, 2008).”
BackgroundXiao, X. (1999) · The EMBO Journal · doi:10.1093/emboj/18.21.5943 · Cited by 550
Wandinger, S. K., Richter, K., & Buchner, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800007200 · Cited by 546
Solit, D. B., Zheng, F. F., Drobnjak, M., Münster, P. N., Higgins, B., Verbel, D., Heller, G., Tong, W. P., Cordon‐Cardo, C., Agus, D. B., et al. (2002) · PubMed · Cited by 433
Non-Oncogene Addiction and the Stress Phenotype of Cancer Cells
Solimini, N. L., Luo, J., & Elledge, S. J. (2007) · Cell · doi:10.1016/j.cell.2007.09.007 · Cited by 365
Estrogen receptor and breast cancer
Sommer, S., & Fuqua, S. A. W. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0389 · Cited by 355
PI3K/PTEN signaling in tumorigenesis and angiogenesis
Jiang, B.-H., & Liu, L.-Z. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.09.008 · Cited by 345
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)
Duensing, A., Medeiros, F., McConarty, B., Joseph, N. E., Panigrahy, D., Singer, S., Fletcher, C. D., Demetri, G. D., & Fletcher, J. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207525 · Cited by 343
Modi, S., Stopeck, A. T., Gordon, M. S., Mendelson, D., Solit, D. B., Bagatell, R., Ma, W., Wheler, J., Rosen, N., Norton, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7960 · Cited by 335
Lewis, J., Devin, A., Miller, A., Lin, Y., Rodriguez, Y., Neckers, L., & Liu, Z.-G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10519 · Cited by 334
Bidirectional Signaling between the Estrogen Receptor and the Epidermal Growth Factor Receptor
Levin, E. R. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0368 · Cited by 329
Inhibitors of the heat shock response: Biology and pharmacology
Powers, M. V., & Workman, P. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.05.040 · Cited by 320
Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D., & Rosen, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609973103 · Cited by 308
Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis
Powers, M. V., Clarke, P. A., & Workman, P. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.002 · Cited by 307
Altered Hsp90 function in cancer: A unique therapeutic opportunity
Bagatell, R., & Whitesell, L. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1021.3.8 · Cited by 302
Fujimoto, J., Shiota, M., Iwahara, T., Seki, N., Satoh, H., Mori, S., & Yamamoto, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4181 · Cited by 289
Ebert, B. L., & Bunn, H. F. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4089 · Cited by 282
Dias, S., Shmelkov, S. V., Lam, G., & Rafii, S. (2002) · Blood · doi:10.1182/blood.v99.7.2532 · Cited by 260
Development and application of Hsp90 inhibitors
Solit, D. B., & Chiosis, G. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.007 · Cited by 251
Nimmanapalli, R., O’Bryan, E., & Bhalla, K. N. (2001) · PubMed · Cited by 242
Self-citationMartin, M. B., Franke, T. F., Stoica, G. E., Chambon, P., Katzenellenbogen, B. S., Stoica, B. A., McLemore, M. S., Olivo, S. E., & Stoica, A. (2000) · Endocrinology · doi:10.1210/endo.141.12.7836 · Cited by 231
Apoptosis: Cell death defined by caspase activation
Samali, A., Zhivotovsky, B., Jones, D., Nagata, S., & Orrenius, S. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400520 · Cited by 220
Xu, W., & Neckers, L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2966 · Cited by 218
Mimnaugh, E. G., Xu, W., Vos, M., Yuan, X., Isaacs, J. S., Bisht, K. S., Gius, D., & Neckers, L. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.551.3.5 · Cited by 210
Whitesell, L., Sutphin, P. D., Pulcini, E. J., Martinez, J. D., & Cook, P. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1517 · Cited by 206
Webb, C. P., Hose, C. D., Koochekpour, S., Jeffers, M., Oskarsson, M. K., Sausville, E. A., Monks, A. P., & Woude, G. F. V. (2000) · PubMed · Cited by 168
Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers
Rangel, L. B. A., Agarwal, R., Sherman-Baust, C. A., de Mello-Coelho, V., Pizer, E. S., Ji, H., Taub, D. D., & Morin, P. J. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.10.1142 · Cited by 166
Banerji, U., Walton, M., Raynaud, F., Grimshaw, R., Kelland, L., Valenti, M., Judson, I., & Workman, P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0518 · Cited by 164
Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance
Shimamura, T., Li, D., Ji, H., Haringsma, H. J., Liniker, E., Borgman, C. L., Lowell, A. M., Minami, Y., McNamara, K. L., Perera, S. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5428 · Cited by 164
Min, J.-N., Huang, L., Zimonjic, D. B., Moskophidis, D., & Mivechi, N. F. (2007) · Oncogene · doi:10.1038/sj.onc.1210317 · Cited by 162
Fiskus, W. C., Ren, Y., Mohapatra, A., Bali, P., Mandawat, A., Rao, R., Herger, B. E., Yang, Y., Atadja, P. W., Wu, J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3093 · Cited by 156
Self-citationControl of estrogen receptor ligand binding by Hsp90
Fliss, A., Benzeno, S., Rao, J., & Caplan, A. J. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00037-6 · Cited by 155
Fumo, G., Akin, C., Metcalfe, D. D., & Neckers, L. (2003) · Blood · doi:10.1182/blood-2003-07-2477 · Cited by 149
Fiskus, W. C., Pranpat, M., Bali, P., Balasis, M. E., Kumaraswamy, S., Boyapalle, S., Rocha, K., Wu, J., Giles, F. J., Manley, P. W., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4639 · Cited by 145
Self-citationInhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
Srethapakdi, M., Liu, F., Tavorath, R., & Rosen, N. X. (2000) · PubMed · Cited by 136
Gabai, V. L., Budagova, K. R., & Sherman, M. Y. (2005) · Oncogene · doi:10.1038/sj.onc.1208495 · Cited by 131
Mhaka, A. M., Gady, A. M., Rosen, D. M., Lo, K.-M., Gillies, S. D., & Denmeade, S. R. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.6.846 · Cited by 105
Bonvini, P., Rosa, H. D., Vignes, N., & Rosolen, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3531 · Cited by 92
Beliakoff, J., Bagatell, R., Paine-Murrieta, G. D., Taylor, C. W., Lykkesfeldt, A. E., & Whitesell, L. J. (2003) · PubMed · Cited by 85
Cao, X., Bloomston, M., Zhang, T., Frankel, W. L., Jia, G., Wang, B., Hall, N. C., Koch, R. M., Cheng, H., Knopp, M. V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1607 · Cited by 83
Genomic analysis of heat-shock factor targets in Drosophila
Birch‐Machin, I., Gao, S., Huen, D. S., McGirr, R., H.White, R. A., & Russell, S. R. H. (2005) · Genome biology · doi:10.1186/gb-2005-6-7-r63 · Cited by 82
Rahmani, M., Reese, E., Dai, Y., Bauer, C., Kramer, L. B., Huang, M., Jove, R., Dent, P., & Grant, S. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.007831 · Cited by 82
V600E B‐Rafはその安定性にHsp90シャペロンを要求し,Hsp90阻害剤への応答として分解される
Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D. B., & Rosen, N. X. (2006) · Proceedings of the National Academy of Sciences · Cited by 65
Banerji, U., Sain, N., Sharp, S. Y., Valenti, M. R., Asad, Y. J., Ruddle, R. R., Raynaud, F. I., Walton, M. I., Eccles, S. A., Judson, I. R., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0662-x · Cited by 40
Banerji, U., Sain, N., Sharp, S. Y., Valenti, M. R., Asad, Y. J., Ruddle, R. R., Raynaud, F. I., Walton, M. I., Eccles, S. A., Judson, I. R., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3674-9 · Cited by 35
Cited by
Cellular Stress Responses: Cell Survival and Cell Death
Fulda, S., Gorman, A. M., Hori, O., & Samali, A. (2010) · International Journal of Cell Biology · doi:10.1155/2010/214074 · Cited by 1,519
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
Protein Folding in the Cytoplasm and the Heat Shock Response
Vabulas, R. M., Raychaudhuri, S., Hayer-Hartl, M., & Hartl, F. U. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004390 · Cited by 428
Inhibition of HSP90 molecular chaperones: moving into the clinic
Garcia-Carbonero, R., Carnero, A., & Paz-Ares, L. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70169-4 · Cited by 351
Biological Effects of Human Exposure to Environmental Cadmium
Peana, M., Pelucelli, A., Chasapis, C. T., Perlepes, S. P., Bekiari, V., Medici, S., & Zoroddu, M. A. (2022) · Biomolecules · doi:10.3390/biom13010036 · Cited by 323
Metadata
- Authors
- Mahalingam, D., Swords, R., Carew, J. S., Nawrocki, S. T., Bhalla, K., & Giles, F. J.
- Venue
- British Journal of Cancer
- Published
- 2009-04-28
- Volume
- 100
- Issue
- 10
- Pages
- 1523-1529
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1966492828
- Cited by
- 317
- References
- 59
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.